Recruitment of subjects into clinical trials for Alzheimer disease

• Published in: The Journal of the American Osteopathic Association Vol. 110; no. 9 Suppl 8; pp. S43 - S49
• Main Authors: Knebl, Janice A, Patki, Deepti
• Format: Journal Article
• Language: English
• Published: United States 01-09-2010
• Subjects: Alzheimer Disease - drug therapy; Alzheimer Disease - pathology; Biomedical Research - methods; Clinical Trials as Topic - methods; Ethics Committees, Research; Humans; Informed Consent; Patient Selection; Psychological Tests
• EISSN: 1945-1997

Alzheimer disease is a devastating neurodegenerative disorder affecting millions of Americans. It reduces the ability of the individual to remain independent, places a burden on caregivers, and substantially increases healthcare costs. New treatments are being tested in numerous clinical trials with the goal of preventing or delaying the onset of Alzheimer disease, slowing or modifying the disease's course, or finding a cure for patients with the disease. Alzheimer disease research can successfully proceed only if individuals who have this illness are willing to participate in clinical trials. However, recruitment and retention of subjects in clinical trials for Alzheimer disease is a challenging task. Furthermore, because of reductions in decision-making capacities of individuals with Alzheimer disease, clinical trials also need to involve caregivers. The present article delineates unique hurdles encountered in the recruitment process for Alzheimer disease clinical trials. The article also identifies strategies for effective recruitment of subjects in Alzheimer disease clinical trials, including guidelines to help principal investigators and clinical research coordinators reach recruitment goals.